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A B S T R A C T
Background
Exclusively breast milk-fed preterm infants may accumulate nutrient deﬁcits leading to extrauterine growth restriction. Feeding preterm
infants with multi-nutrient fortiﬁed human breast milk rather than unfortiﬁed breast milk may increase nutrient accretion and growth
rates and may improve neurodevelopmental outcomes.
Objectives
To determine whether multi-nutrient fortiﬁed human breast milk improves important outcomes (including growth and development)
over unfortiﬁed breast milk for preterm infants without increasing the risk of adverse effects (such as feed intolerance and necrotising
enterocolitis).
Search methods
We used the standard search strategy of the Cochrane Neonatal Review Group. This included electronic searches of the Cochrane
Central Register of Controlled Trials (CENTRAL; 2016, Issue 2), MEDLINE, EMBASE and the Cumulative Index to Nursing and
Allied Health Literature (CINAHL) (until February 2016), as well as conference proceedings and previous reviews.
Selection criteria
Randomised and quasi-randomised controlled trials that compared feeding preterm infants with multi-nutrient (protein and energy
plus minerals, vitamins or other nutrients) fortiﬁed human breast milk versus unfortiﬁed (no added protein or energy) breast milk.
Data collection and analysis
We extracted data using the standard methods of the Cochrane Neonatal Review Group. We separately evaluated trial quality, data
extracted by two review authors and data synthesised using risk ratios (RRs), risk differences andmean differences (MDs).We assessed the
quality of evidence at the outcome level using the Grading of Recommendations Assessment, Development and Evaluation (GRADE)
approach.
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Main results
We identiﬁed 14 trials in which a total of 1071 infants participated. The trials were generally small and weak methodologically. Meta-
analyses provided low-quality evidence that multi-nutrient fortiﬁcation of breast milk increases in-hospital rates of growth (MD 1.81
g/kg/d, 95% conﬁdence interval (CI) 1.23 to 2.40); length (MD 0.12 cm/wk, 95% CI 0.07 to 0.17); and head circumference (MD
0.08 cm/wk, 95% CI 0.04 to 0.12). Only very limited data are available for growth and developmental outcomes assessed beyond
infancy, and these show no effects of fortiﬁcation. The data did not indicate other potential beneﬁts or harms and provided low-quality
evidence that fortiﬁcation does not increase the risk of necrotising enterocolitis in preterm infants (typical RR 1.57, 95% CI 0.76 to
3.23; 11 studies, 882 infants).
Authors’ conclusions
Limited available data do not provide strong evidence that feeding preterm infants with multi-nutrient fortiﬁed breast milk compared
with unfortiﬁed breast milk affects important outcomes, except that it leads to slightly increased in-hospital growth rates.
P L A I N L A N G U A G E S U M M A R Y
Multi-nutrient fortification of breast milk for preterm infants
Review question:Does feeding preterm infants with breast milk fortiﬁed with extra nutrients (including protein and energy) compared
with unfortiﬁed breast milk increase growth rate and improve development?
Background: Breast milk alone may not provide preterm infants with sufﬁcient quantities of nutrients to support optimal growth and
development. Mutli-nutrient fortiﬁers (powder or liquid supplements of protein, energy from carbohydrates or fat and other nutrients,
usually extracted from cow’s milk) can be added to breast milk to increase nutrient content by about 10%. Feeding preterm infants,
particularly very preterm infants, with multi-nutrient fortiﬁed breast milk may increase nutrient intake and growth rates, and may
improve development.
Study characteristics: We found 14 trials; most were small (involving 1071 infants in total) and were ﬂawed methodologically.
Key results: Multi-nutrient fortiﬁcation of breast milk for preterm infants is associated with small increases in rates of weight gain,
length gain and head growth during neonatal unit admission. Only very limited data are available for growth and developmental
outcomes assessed beyond infancy, and these show no effects of fortiﬁcation. Trials report no consistent evidence of other potential
beneﬁts or harms of fortiﬁcation, including effects on risk of feeding or bowel problems.
Conclusions: Although available trial data show that multi-nutrient fortiﬁcation increases growth rates of preterm infants during their
initial hospital admission, they do not provide consistent evidence on effects on longer-term growth or development. Additional trials
are needed to resolve this issue.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Patient or population: preterm infants
Setting: healthcare sett ing
Intervention: f ort if ied breast m ilk
Comparison: unfort if ied breast m ilk
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Risk with unfortified breast
milk
Risk with fortified breast
milk
Weight gain (g/ kg/ d) Comparator Mean weight gain was 1.81
g/ kg/ d more (1.23 more to
2.4 more)
- 635
(10 RCTs)
⊕⊕©©
Lowa,b
Length gain (cm/ wk) Comparator Mean length gain was 0.12
cm/ wk more (0.07 more to
0.17 more)
- 555
(8 RCTs)
⊕⊕©©
Lowa,b
Head growth (cm/ wk) Comparator Mean head growth was 0.
08 cm/ wk more (0.04 more
to 0.12 more)
- 555
(8 RCTs)
⊕⊕⊕©
Moderateb
Mental development index
(MDI) at 18 months
Comparator Mean MDI was 2.2 more (3.
35 fewer to 7.75 more)
- 245
(1 RCT)
⊕⊕⊕©
Moderatec
Psychomotor development
index (PDI) at 18 months
Comparator Mean PDI was 2.4 more (1.
9 fewer to 6.7 more)
- 245
(1 RCT)
⊕⊕⊕©
Moderatec
Necrot ising enterocolit is Study populat ion RR 1.57
(0.76 to 3.23)
882
(11 RCTs)
⊕⊕©©
Lowb,d
25 per 1000 40 per 1000
(19 to 82)
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* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI - conf idence interval; RR - risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect but may be substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of the ef fect
aUnexplained heterogeneity
bUncertainty about methods used to generate random sequence, conceal allocat ion and blind assessments in most trials
cEstimates of ef fect consistent with both substant ial harms and benef its
d95% CI of RR consistent with 3-fold increase in risk with intervent ion
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B A C K G R O U N D
Description of the condition
Most preterm infants accumulate energy, protein, mineral and
other nutrient deﬁcits during the initial neonatal unit admis-
sion (Embleton 2001; Cooke 2004). By the time they are ready
to go home, typically at around 36 to 40 weeks’ postmenstrual
age, many infants, especially those born very preterm or very
low birth weight (VLBW), are substantially growth-restricted rel-
ative to their term-born peers (Ehrenkranz 1999; Steward 2002;
Clark 2003; Dusick 2003). Although very preterm or VLBW in-
fants usually attain some “catch-up” growth following hospital
discharge, growth deﬁcits can persist through childhood and ado-
lescence and into adulthood (Dusick 2003; Euser 2008). Slow
postnatal growth is associated with neurodevelopmental impair-
ment in later childhood andwith poorer cognitive and educational
outcomes (Brandt 2003; Leppanen 2014). Preterm infants who
have accumulated mineral deﬁcits have higher risks of metabolic
bone disease and slow skeletal growth compared with infants
born at term, although uncertainty remains about long-term ef-
fects on bone mass and health (Fewtrell 2011). Furthermore, re-
searchers have expressed concern that nutritional deﬁciency and
growth restriction in utero and during early infancy may have
consequences for long-term metabolic and cardiovascular health
(Embleton 2013; Lapillonne 2013).
Description of the intervention
Multi-nutrient fortification of breast milk
Human breast milk is the recommended form of enteral nutrition
for newborn infants for at least the ﬁrst six months of postnatal
life (Johnston 2012). Breast milk alone, however, may not meet
the recommended nutritional needs of growing preterm infants
(Embleton 2007; Agostoni 2010). International consensus guide-
lines state that “standard” volumes (about 150 to 180 mL/kg/d)
of breast milk do not provide the recommended amount of energy
(110 to 135 kcal/kg/d) or protein (3.5 to 4.5 g/kg/d) to meet the
metabolic needs of preterm infants (AAP 2004; Agostoni 2010).
The strategy most commonly employed in neonatal care facili-
ties in high-income countries to address these potential nutrient
deﬁcits is to supplement breastmilkwith extra nutrients, usually in
the form of a powder or liquid “multi-nutrient fortiﬁer” (Gregory
2012; Klingenberg 2012; Cormack 2013; Tudehope 2013; Dutta
2015). Most commercially available multi-nutrient fortiﬁers are
derived from cow’s milk, but fortiﬁers derived from human milk
have been developed recently (Rochow 2015).
Fortiﬁers are intended to be mixed with expressed breast milk with
the aim of achieving about 10% nutrient enrichment while main-
taining optimal protein-to-energy ratios to promote lean mass
growth (Embleton 2007; Agostoni 2010; Johnston 2012; Moya
2012; Tudehope 2013). Multi-nutrient fortiﬁcation may be espe-
cially important for infants who receive donated (donor) expressed
breast milk, which contains lower levels of protein, energy and
minerals than their ownmother’s expressed breastmilk (Arslanoglu
2013). Commercially available fortiﬁers are expensive, and their
use is less feasible in resource-poor settings in low- or middle-in-
come countries (Chawla 2008; Kler 2015). An alternative strategy,
more commonly employed in resource-limited settings, is to en-
rich breast milk by adding cow’s milk formula powder to achieve
the required level of nutrient enrichment (Gross 1993).
Targeted and adjustable fortification
Nutrient (especially energy and protein) content of expressed
breast milk varies between mothers and between different batches
of a woman’s expressed breast milk (de Halleux 2013). If the nu-
trient levels in expressed breast milk are measured, the amount
of fortiﬁer added can be targeted (also referred to as individu-
alised) to achieve a desired overall content (Rochow 2013; Rochow
2015). The level of fortiﬁcation may be adjusted in response to
the metabolic demands and responses of individual infants, for
example, by titration to the infant’s serum urea level (Arslanoglu
2010).
How the intervention might work
Feeding preterm infants with human milk fortiﬁed with energy
and protein (as well as minerals and other nutrients) may be ex-
pected to promote nutrient accretion and growth (increase in
weight, length and head circumference). Higher levels of nutrient
intake during this critical period may be especially important for
infants who are not able to consume larger quantities of milk, who
have slow growth or who have ongoing additional nutritional and
metabolic requirements (Agostoni 2010).
A potential disadvantage of multi-nutrient fortiﬁcation is that in-
creasing nutrient density and osmolarity of breast milk might in-
terfere with gastric emptying and intestinal peristalsis, resulting
in feed intolerance or increasing the risk of necrotising entero-
colitis (Ewer 1996; McClure 1996; Gathwala 2008; Yigit 2008;
Morgan 2011). Several cases of subacute bowel obstruction due to
impaction with “milk curd” have been reported in very preterm
infants fed with multi-nutrient fortiﬁed expressed breast milk, pu-
tatively due to the high calcium content causing fat malabsorp-
tion (Flikweert 2003;Wagener 2009; Stanger 2014). Investigators
have been concerned that rapid growth with accelerated weight
gain during this critical early phase might be associated with al-
tered fat distribution and related ’programmed’ metabolic conse-
quences that may increase long-term risks of insulin resistance and
hypertension (Euser 2005; Singhal 2007; Euser 2008).
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Why it is important to do this review
Given the potential for multi-nutrient fortiﬁcation of breast milk
to affect important outcomes for preterm infants, this review aims
to detect, appraise and synthesise available evidence from ran-
domised controlled trials to inform practice and research.
O B J E C T I V E S
To determine whether multi-nutrient fortiﬁed human breast milk
improves important outcomes (including growth and develop-
ment) over unfortiﬁed breast milk for preterm infants without in-
creasing the risk of adverse effects (such as feed intolerance and
necrotising enterocolitis).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised and quasi-randomised controlled trials, including
cluster-randomised controlled trials. We did not include cross-
over trials.
Types of participants
Preterm (< 37 weeks’ gestational age) and low birth weight (< 2500
g) infants receiving enteral breast milk.
Types of interventions
Fortiﬁcationof humanbreastmilk (expressedmaternal or donor or
both) with both energy (carbohydrate or fat) and protein. Multi-
nutrient fortiﬁers additionally could contain minerals, iron, vita-
mins or other nutrients. Multi-nutrient fortiﬁers could be cow (or
another animal) milk-based or human milk-based. The control
group should not have received energy or protein fortiﬁcation but
could have received milk supplemented with minerals, iron, vita-
mins or other nutrients.
Eligible trials should have planned to allocate the trial interven-
tion for a sufﬁcient period (at least two weeks) to allowmeasurable
effects on growth. Infants in comparison groups within each trial
should have received similar care other than the level of fortiﬁca-
tion of breast milk. No between-group differences in target levels
of volume of milk intake should have occurred.
We did not include trials of:
• targeted fortiﬁcation (vs standard fortiﬁcation);
• adjustable fortiﬁcation (vs standard fortiﬁcation);
• early versus later introduction of multi-nutrient fortiﬁer; or
• human milk-based versus cow milk-based fortiﬁer.
Separate Cochrane reviews will consider these comparisons.
Types of outcome measures
Primary outcomes
• Growth: weight, length, head growth, skinfold thickness,
body mass index and measures of body composition (lean/fat
mass) and growth restriction (proportion of infants who remain
< 10th percentile for the index population distribution of
weight, length or head circumference).
• Neurodevelopmental outcomes assessed after 12 months
post term: neurological evaluations, developmental scores and
classiﬁcations of disability, including auditory and visual
disability. We deﬁned neurodevelopmental impairment as the
presence of one or more of the following: non-ambulant cerebral
palsy, developmental quotient more than two standard
deviations below the population mean and blindness (visual
acuity < 6/60) or deafness (any hearing impairment requiring or
unimproved by ampliﬁcation).
Secondary outcomes
• Duration of hospital admission (weeks).
• Feed intolerance that results in cessation or reduction in
enteral feeding.
• Necrotising enterocolitis (modiﬁed Bell stage 2/3; Walsh
1986).
• Measures of bone mineralisation such as serum alkaline
phosphatase level, or bone mineral content assessed by dual
energy x-ray absorptiometry (DEXA) and clinical or radiological
evidence of rickets on long-term follow-up (restricted to trials
without mineral supplementation of the control group).
• Measures of long-term metabolic or cardiovascular health,
including insulin resistance, obesity, diabetes and hypertension.
Search methods for identification of studies
We used the standard search strategy of the Cochrane Neonatal
Review Group.
Electronic searches
We searched MEDLINE, EMBASE, the Cumulative Index to
Nursing and Allied Health Literature (CINAHL) and Maternity
and Infant Care (see Appendix 1).
We searched ClinicalTrials.gov and Current Controlled Trials for
completed or ongoing trials.
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Searching other resources
We examined the references in studies identiﬁed as potentially rel-
evant. We also searched abstracts from annual meetings of the Pe-
diatric Academic Societies (1993 to 2015), the European Society
for Paediatric Research (1995 to 2015), the UK Royal College of
Paediatrics and Child Health (2000 to 2016) and the Perinatal
Society of Australia and New Zealand (2000 to 2015). We con-
sidered trials reported only as abstracts to be eligible if sufﬁcient
information was available from the report, or from contact with
study authors, to fulﬁl the inclusion criteria.
Data collection and analysis
We used the standard methods of the Cochrane Neonatal Review
Group.
Selection of studies
One review author (JB) screened titles and abstracts of all records
identiﬁed by the search and coded records as “order” or “exclude”.
A second review author (WM) assessed all records coded as “order”
and made the ﬁnal decision about which records were ordered as
full-text articles. JB read the full texts and used a checklist to assess
each article’s eligibility for inclusion on the basis of pre-speciﬁed
inclusion and exclusion criteria. MM checked these decisions.
Data extraction and management
Two review authors (JB and WM) extracted data independently
using a data collection form to aid extraction of information on
design, methods, participants, interventions, outcomes and treat-
ment effects from each included study. We discussed disagree-
ments until we reached consensus. If data from the trial reports
were insufﬁcient, we contacted trialists for further information.
Assessment of risk of bias in included studies
We used criteria and standard methods of the Cochrane Neonatal
Review Group to assess the methodological quality of included
trials. Two review authors (JB and WM) assessed risk of bias.
We resolved disagreements by discussion and requested additional
information from trial authors to clarify methods and results if
necessary.
We made explicit judgements about whether studies are at high
risk of bias across four domains according to the criteria suggested
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
• Random sequence generation: We categorised the method
used to generate the allocation sequence as:
◦ low risk - any truly random process (e.g. random
number table, computer random number generator);
◦ high risk - any non-random process (e.g. odd or even
date of birth, hospital or clinic record number); or
◦ unclear risk - no or unclear information provided.
• Allocation concealment: We categorised the method used
to conceal the allocation sequence as:
◦ low risk (e.g. telephone or central randomisation,
consecutively numbered sealed opaque envelopes);
◦ high risk - open random allocation (e.g. unsealed or
non-opaque envelopes, alternation, date of birth); or
◦ unclear risk - no or unclear information provided.
• Blinding: We assessed blinding of participants, clinicians,
caregivers and outcome assessors separately for different
outcomes and categorised the methods as:
◦ low risk;
◦ high risk; or
◦ unclear risk.
• Incomplete outcome data: We described the completeness
of data from the analysis including attrition and exclusions for
each outcome and reasons for attrition or exclusion, when
reported. We assessed whether missing data were balanced across
groups or were related to outcomes. When sufﬁcient information
was reported or supplied by the trial authors, we planned to
reinstate missing data in the analyses. We categorised
completeness as:
◦ low risk: ≤ 10% missing data;
◦ high risk: > 10% missing data; or
◦ unclear risk: no or unclear information provided.
Measures of treatment effect
We analysed treatment effects in the individual trials using Review
Manager 5.3 and reported risk ratios (RRs) and risk differences
(RDs) for dichotomous data, andmean differences (MDs) for con-
tinuous data, with respective 95% conﬁdence intervals (CIs). We
determined the number needed to treat for an additional beneﬁcial
outcome (NNTB) or an additional harmful outcome (NNTH)
for analyses with a statistically signiﬁcant difference in the RD.
Unit of analysis issues
The unit of analysis was the participating infant in individually
randomised trials. For cluster-randomised trials (had we identiﬁed
any for inclusion), we planned to undertake analyses at the level
of the individual while accounting for clustering in the data using
methods recommended in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
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Dealing with missing data
We requested additional data from trial investigators when data
on important outcomes were missing or were reported unclearly.
When data were still missing, we examined the impact on effect
size estimates in sensitivity analyses.
Assessment of heterogeneity
We examined treatment effects in individual trials and heterogene-
ity between trial results by inspecting the forest plots if more than
one trial was included in a meta-analysis. We calculated the I²
statistic for each analysis to quantify inconsistency across studies
and to describe the percentage of variability in effect estimates that
may be due to heterogeneity rather than sampling error. If we de-
tected substantial (I² > 50%) heterogeneity, we explored possible
causes (e.g. differences in study design, participants, interventions
or completeness of outcome assessments) in sensitivity analyses.
Assessment of reporting biases
We inspected funnel plots for asymmetry if more than ﬁve trials
were included in a meta-analysis.
Data synthesis
We used a ﬁxed-effect model for meta-analyses.
Quality of evidence
We assessed the quality of evidence for the main comparison at
the outcome level using the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) approach (Guyatt
2011a). This considers evidence from randomised controlled trials
as high quality that may be downgraded on the basis of consider-
ation of any of ﬁve areas.
• Design (risk of bias).
• Consistency across studies.
• Directness of the evidence.
• Precision of estimates.
• Presence of publication bias.
The GRADE approach results in assessment of the quality of a
body of evidence according to four grades (Schünemann 2013).
• High: We are very conﬁdent that the true effect lies close to
the estimate of effect.
• Moderate: We are moderately conﬁdent in the effect
estimate: The true effect is likely to be close to the estimate of
effect but may be substantially different.
• Low: Our conﬁdence in the effect estimate is limited: The
true effect may be substantially different from the estimate of
effect.
• Very low: We have very little conﬁdence in the effect
estimate: The true effect is likely to be substantially different
from the estimate of effect.
Two review authors (JB and WM) assessed independently the
quality of the evidence found for outcomes identiﬁed as critical
or important for clinical decision making (growth, development,
necrotising enterocolitis).
In cases for which we considered risk of bias arising from inad-
equate concealment of allocation, randomised assignment, com-
plete follow-up or blinded outcome assessment to reduce our con-
ﬁdence in the effect estimates, we downgraded the quality of evi-
dence accordingly (Guyatt 2011b). We evaluated consistency on
the basis of similarity of point estimates, extent of overlap of con-
ﬁdence intervals and statistical criteria, including measurement of
heterogeneity (I²). We downgraded the quality of evidence when
inconsistency across study results was large and unexplained (i.e.
some studies suggested important beneﬁt, and others no effect or
harm with no explanation) (Guyatt 2011c). We assessed precision
accordingly with the 95% conﬁdence interval (CI) around the
pooled estimation (Guyatt 2011d). When trials were conducted
in populations other than the target population, we downgraded
the quality of evidence because of indirectness (Guyatt 2011e).
We entered data (pooled estimates of effects and corresponding
95% CIs) and explicit judgements for each of the above aspects
assessed into the Guideline Development Tool, the software used
to create ’Summary of ﬁndings (SoF)’ tables (GRADEpro 2008).
We explained our assessment of study characteristics in footnotes
in the SoF table.
Subgroup analysis and investigation of heterogeneity
We planned to undertake these subgroup analyses, when possible.
• Very preterm (< 32 weeks’ gestation) or VLBW (< 1500 g)
infants (vs infants 32 to 36 weeks’ gestation or birth weight 1500
to 2499 g).
• Fortifcation of donor breast milk (vs maternal expressed
breast milk).
• Trials using fortiﬁer extracted from human milk (vs cow
milk-based fortiﬁer).
• Trials supplementing breast milk with infant formula (vs
cow milk-based fortiﬁer).
• Trials conducted in low- and middle-income countries
versus high-income countries (see http://data.worldbank.org/
about/country-classiﬁcations).
R E S U L T S
Description of studies
See also Characteristics of included studies and Characteristics of
excluded studies.
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Results of the search
See Figure 1 for an illustration of the study selection process.
Figure 1. Flow diagram.
Included studies
We included in this review 14 trials (13 primary publications)
in which 1071 infants participated that met our inclusion crite-
ria (Modanlou 1986; Gross 1987 (1); Gross 1987 (2); Pettifor
1989; Polberger 1989; Porcelli 1992; Zuckerman 1994; Lucas
1996; Wauben 1998; Nicholl 1999; Faerk 2000; Bhat 2003;
Mukhopadhyay 2007; Gathwala 2012). Sample sizes ranged be-
tween 14 and 275 participants.
All trials were set in specialist paediatric hospital settings, mainly
neonatal intensive care units. Ten trials were single-centre tri-
als (Modanlou 1986; Gross 1987 (1); Gross 1987 (2); Pettifor
1989; Porcelli 1992; Zuckerman 1994; Nicholl 1999; Bhat 2003;
Mukhopadhyay 2007;Gathwala 2012), and each of the remaining
four was conducted at two centres (Polberger 1989; Lucas 1996;
Wauben 1998; Faerk 2000).
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We noted that ﬁve trials were conducted in Europe (Polberger
1989; Porcelli 1992; Lucas 1996; Nicholl 1999; Faerk 2000),
four in North America (Modanlou 1986; Gross 1987 (1);
Gross 1987 (2); Wauben 1998), three in Asia (Bhat 2003;
Mukhopadhyay 2007; Gathwala 2012) and two in Africa (Pettifor
1989; Zuckerman 1994). Publication dates span four decades,
ranging from 1986 to 2012.
Participants
All trials includedpretermor lowbirthweight infants and excluded
those with major congenital abnormalities. Eight trials restricted
participation to very preterm or VLBW infants (Modanlou 1986;
Pettifor 1989; Polberger 1989; Zuckerman 1994; Nicholl 1999;
Faerk 2000; Bhat 2003; Mukhopadhyay 2007). The other trials
speciﬁed the following as anupper birthweight eligibility criterion:
• 1600 g (Gross 1987 (1); Gross 1987 (2)).
• 1800 g (Gathwala 2012; Wauben 1998).
• 1850 g (Lucas 1996).
• 2000 g (Porcelli 1992).
Average gestational age of included infants across all trials was 30
weeks. The nature of the intervention required that babies in all
trials must tolerate enteral feeds and mothers needed to supply
expressed breast milk.
Interventions
For all infants, trials relied largely on provision of the mother’s
own expressed breast milk. Three trials used only themother’s own
milk (Pettifor 1989; Zuckerman 1994; Wauben 1998). It was not
always reported how feeds were made up if the mother could not
provide sufﬁcient milk, but in some studies, infants were excluded
on this basis. Seven trials supplemented mother’s own milk with
donor (or “bank”)milk (Gross 1987 (1); Gross 1987 (2); Polberger
1989; Porcelli 1992; Nicholl 1999; Faerk 2000; Mukhopadhyay
2007). Investigators in the remaining four trials used formula to
top feeds up to the required volume (Modanlou 1986; Lucas 1996;
Bhat 2003; Gathwala 2012).
Types of multi-nutrient fortiﬁcation added to milk for infants
in the intervention groups varied. Most trials used a commer-
cially available, cow’s milk-based, powdered preparation contain-
ing varying amounts of protein, fat, carbohydrate, minerals, elec-
trolytes and trace minerals.
• Similac Human Milk Fortiﬁer (HMF; Ross Laboratories):
Gross 1987 (1); Gross 1987 (2) [Gross 1987 (1) included a third
group of infants receiving human milk fortiﬁed with formula
(see below).
• FM85 (Nestlè): Porcelli 1992.
• Enfamil HMF (Mead Johnson): Lucas 1996.
• Nutriprem (Cow & Gate Nutricia): Nicholl 1999.
• Eoprotin (Milupa): Faerk 2000.
• Lactodex HMF (Raptakos Brett): Mukhopadhyay 2007;
Gathwala 2012.
• Trial-speciﬁc multi-nutrient fortiﬁer (Wyeth-Ayerst):
Wauben 1998.
Two trials mixed equal volumes of human milk and preterm for-
mula.
• Similac Special Care, Ross Laboratories: Gross 1987 (1).
• Alprem (Nestlè): Zuckerman 1994.
Three trials did not specify the name or manufacturer of themulti-
nutrient fortiﬁer used: Modanlou 1986; Polberger 1989; Bhat
2003.
All trials used a ﬁxed, pre-speciﬁed amount of fortiﬁer for all in-
fants in the intervention group. Some trials titrated the amount
of fortiﬁer per feed to try to prevent feed intolerance.
Comparators
Most trials added vitamins, minerals or other nutrients to con-
trol infants’ feeds as part of standard hospital practice. Four tri-
als provided all infants with additional vitamin D (Pettifor 1989;
Porcelli 1992; Zuckerman 1994; Faerk 2000). Five trials pro-
vided all infants with several vitamins and minerals (added to
feeds for infants in the control group, and included in the fortiﬁer
or added separately for infants in the intervention group) (Gross
1987 (1); Gross 1987 (2); Polberger 1989; Lucas 1996; Wauben
1998). Researchers in ﬁve trials gave no supplements at all to con-
trol group infants (Modanlou 1986; Nicholl 1999; Bhat 2003;
Mukhopadhyay 2007; Gathwala 2012).
Outcomes
Investigators in all included trials assessed at least one of our pre-
speciﬁed outcomes of interest. Ten trials contributed growth rate
data (Modanlou 1986; Gross 1987 (1); Gross 1987 (2); Pettifor
1989; Polberger 1989; Porcelli 1992; Lucas 1996; Wauben 1998;
Nicholl 1999; Mukhopadhyay 2007). Only Lucas 1996 reported
size and neurodevelopmental data at follow-up beyond hospital
discharge.
Excluded studies
See Characteristics of excluded studies for details. We excluded:
• Carey 1987 and Greer 1988 because they used fortiﬁcation
with protein only (no fortiﬁcation with fat or carbohydrate);
• Tarcan 2004; Arslanoglu 2009; Reali 2010; and Hair 2014
because they were not randomised controlled trials; and
• Abrams 2014 because it compared human versus cow’s
milk-based protein fortiﬁcation rather than fortiﬁcation versus
no fortiﬁcation.
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Risk of bias in included studies
Overall, we found risk of bias difﬁcult to assess as the result of lim-
ited reporting. Consequently, we scored most items as “unclear”
(Figure 2).
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Risk of selection bias was largely unclear.Only four trials described
adequate methods of random sequence generation (Lucas 1996;
Wauben 1998; Mukhopadhyay 2007; Gathwala 2012). Only two
explicitly described adequate allocation concealment methods (
Lucas 1996; Nicholl 1999). Zuckerman 1994 was at high risk
of selection bias, as investigators performed group allocation in a
quasi-randomised fashion (odd and even hospital numbers).
Blinding
Risk of performance and selection bias was also unclear in most
trials. Several trials were known to be at high risk as reports stated
that personnel and outcome assessors were not blinded (Modanlou
1986; Zuckerman 1994; Lucas 1996; Wauben 1998; Nicholl
1999).
Incomplete outcome data
We judged ﬁve trials to be at high risk of attrition bias (Modanlou
1986; Pettifor 1989; Polberger 1989; Wauben 1998; Faerk 2000)
and all other trials to be at low risk.
Other potential sources of bias
Authors of three trials were employees of the manufacturer of the
fortiﬁer used (Modanlou 1986; Lucas 1996; Wauben 1998). The
manufacturer of the fortiﬁer used funded two trials (Pettifor 1989;
Lucas 1996).
Effects of interventions
See: Summary of findings for the main comparison Multi-
nutrient fortiﬁcation of human milk for preterm infants
Growth rates (Outcomes 1.1 to 1.6)
Weight gain (Analysis 1.1):We obtained data from 10 trials includ-
ing 635 infants (Modanlou 1986; Gross 1987 (1); Gross 1987 (2);
Pettifor 1989; Polberger 1989; Porcelli 1992; Lucas 1996;Wauben
1998; Nicholl 1999; Mukhopadhyay 2007). Several trials as well
as a meta-analysis of the data from all trials showed a statistically
signiﬁcantly higher rate of weight gain in the intervention (forti-
ﬁer) group (MD 1.81, 95% CI 1.23 to 2.40 g/kg/d). Substantial
heterogeneity was present in this analysis (I² = 72%) (Figure 3).
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Figure 3. Forest plot of comparison: 1 Fortified breast milk versus unfortified breast milk, outcome: 1.1
Weight gain (g/kg/d).
Length gain (Analysis 1.2): We obtained data from eight trials in-
cluding 555 infants (Modanlou 1986; Gross 1987 (1); Gross 1987
(2); Polberger 1989; Porcelli 1992; Lucas 1996; Wauben 1998;
Mukhopadhyay 2007). Results across individual trials varied, but
a meta-analysis of the data from all trials showed a statistically
signiﬁcantly higher rate of length gain in the fortiﬁed group (MD
0.18, 95% CI 0.10 to 0.26 cm/wk). We detected substantial het-
erogeneity in this analysis (I² = 69%) (Figure 4).
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Figure 4. Forest plot of comparison: 1 Fortified breast milk versus unfortified breast milk, outcome: 1.2
Length gain (cm/wk).
Head growth (Analysis 1.3): We obtained data from eight trials in-
cluding 555 infants (Modanlou 1986; Gross 1987 (1); Gross 1987
(2); Polberger 1989; Porcelli 1992; Lucas 1996; Wauben 1998;
Mukhopadhyay 2007). Results across individual trials varied, but
a meta-analysis of the data from all trials showed a statistically
signiﬁcantly higher rate of head growth in the intervention group
(MD 0.08, 95% CI 0.04 to 0.12 cm/wk). We detected low het-
erogeneity in this analysis (I² = 22%) (Figure 5).
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Figure 5. Forest plot of comparison: 1 Fortified breast milk versus unfortified breast milk, outcome: 1.3
Head growth (cm/wk).
Weight at 12 to 18 months (Analysis 1.4): We obtained data from
Lucas 1996 and Wauben 1998 (270 infants). Neither trial nor a
meta-analysis of the data from both trials showed a statistically
signiﬁcant difference (MD -0.03, 95% CI -0.31 to 0.25 kg).
Length at 12 to 18 months (Analysis 1.5): We obtained data from
Lucas 1996 and Wauben 1998 (270 infants). Neither trial nor a
meta-analysis of the data from both trials showed a statistically
signiﬁcant difference (MD -0.19, 95% CI -0.98 to 0.60 cm).
Head circumference at 12 to 18 months (Analysis 1.6): We obtained
data from Lucas 1996 and Wauben 1998 (270 infants). Neither
trial nor a meta-analysis of the data from both trials showed a
statistically signiﬁcant difference (MD0.10, 95%CI -0.37 to 0.18
cm).
Neurodevelopmental outcomes after 12 months of
age (Outcomes 1.7 and 1.8)
Only one trial (245 infants) reported data on this outcome (Lucas
1996). This trial reported no statistically signiﬁcant differences in:
• mental development index at 18 months (Analysis 1.7):
MD 2.20 (95% CI -3.35 to 7.75); nor
• psychomotor development index at 18 months (Analysis
1.8): MD 2.40 (95% CI -1.90 to 6.70).
Length of hospital stay in weeks (Outcome 1.9)
We obtained data from Zuckerman 1994 and Mukhopadhyay
2007 (210 infants) (Analysis 1.9). Neither trial nor ameta-analysis
of their data showed a statistically signiﬁcant difference (MD0.38,
95% CI -0.16 to 0.93 weeks).
Feed intolerance (Outcome 1.10)
We obtained data from ﬁve trials (Gross 1987 (1); Gross 1987 (2);
Polberger 1989; Wauben 1998; Mukhopadhyay 2007) including
255 infants (Analysis 1.10). Results across individual trials varied,
and a meta-analysis of data showed no statistically signiﬁcant dif-
ferences (typical RR 0.90, 95% CI 0.54 to 1.49).
Necrotising enterocolitis (Outcome 1.11)
We obtained data from 11 trials (Modanlou 1986; Pettifor
1989; Polberger 1989; Porcelli 1992; Zuckerman 1994; Lucas
1996; Wauben 1998; Nicholl 1999; Faerk 2000; Bhat 2003;
Mukhopadhyay 2007) including 882 infants (Analysis 1.11). Re-
sults across individual trials varied, and a meta-analysis of the data
from all trials showed no statistically signiﬁcant differences (typi-
cal RR 1.57, 95% CI 0.76 to 3.23).
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Measures of bone mineralisation (Outcomes 1.12 and
1.13)
Serum alkaline phosphatase (Analysis 1.12): Meta-analysis of data
obtained from ﬁve trials (restricted to trials without mineral sup-
plementation of the control group) showed that the intervention
group had statistically signiﬁcantly lower serum alkaline phos-
phatase (ALP) levels (Modanlou 1986; Pettifor 1989; Zuckerman
1994;Mukhopadhyay 2007;Gathwala 2012): weightedmean dif-
ference (WMD) -126 (95% CI -191 to -62) IU/L. Substantial
heterogeneity was present in this analysis (I² = 58%). Bhat 2003
did not report peak ALP levels but did state that the intervention
group included fewer infants who developed high ALP levels (>
450 IU/L) than were included in the control group (without min-
eral supplementation).
Bone mineral content (Analysis 1.13): Only Pettifor 1989 provided
numerical data and reported a statistically signiﬁcantly higher level
of bone mineral content in the intervention group: WMD 12.0
(95% CI 6.3 to 17.7) mg/cm. Modanlou 1986, Gross 1987 (1)
and Gross 1987 (2) detected no statistically signiﬁcant differences
between control and treatment groups but did not report numer-
ical data for inclusion in meta-analyses.
Measures of metabolic health on long-term follow-up
No included trials reported these measures.
Subgroup analyses
Very preterm or VLBW infants
Meta-analyses of data from trials that restricted participation to
very preterm or VLBW infants showed no substantial differ-
ences in meta-analyses of all trial data (Analysis 1.1; Analysis 1.2;
Analysis 1.3; Analysis 1.9; Analysis 1.10; Analysis 1.11; Analysis
1.12; Analysis 1.13).
Fortifcation of donor breast milk
Seven trials supplemented mother’s own milk with donor (or
“bank”) milk (Gross 1987 (1); Gross 1987 (2); Polberger 1989;
Porcelli 1992; Nicholl 1999; Faerk 2000; Mukhopadhyay 2007).
None of these investigators used donor milk exclusively (or pre-
dominantly), and none reported subgroup data for infants fedwith
donor breast milk exclusively.
Trials using fortifier extracted from human milk (rather
than cow’s milk-based fortifiers)
All trials included in this review used cow’s milk-based fortiﬁers.
Trials supplementing breast milk with infant formula (rather
than breast milk fortifier)
Gross 1987 (2) (for a subset of the intervention group, N = 19) and
Zuckerman 1994 (N = 56) used preterm infant formula to fortify
breast milk in their trials. Gross 1987 (2) reported in-hospital
growth parameters and found effects consistent with the meta-
analyses. Zuckerman 1994 reported data on length of hospital
stay, incidence of necrotising enterocolitis and levels of serum ALP
consistent with the meta-analyses (Analysis 1.9; Analysis 1.11;
Analysis 1.12).
Trials conducted in low- and middle-income countries
Researchers conducted four trials in middle-income countries:
Pettifor 1989 and Zuckerman 1994 in South Africa (upper mid-
dle-income country) and Mukhopadhyay 2007 and Gathwala
2012 in India (lowermiddle-income country). Meta-analyses were
limited and showed no substantial differences from themeta-anal-
yses of all trials together (Analysis 1.1; Analysis 1.2; Analysis 1.3;
Analysis 1.9; Analysis 1.10; Analysis 1.11; Analysis 1.12; Analysis
1.13).
D I S C U S S I O N
Summary of main results
Available evidence from 14 randomised controlled trials suggests
that multi-nutrient fortiﬁcation (both energy and protein, as well
as minerals and vitamins) results in small but statistically signiﬁ-
cant increases in rates of weight gain, length gain and head growth
for preterm infants. However, most trials reported growth param-
eters only over short-term study periods during the initial neonatal
unit admission. Very few data are available for growth and devel-
opmental outcomes assessed beyond infancy, and these show no
statistically signiﬁcant effects of fortiﬁcation. None of these trials
have reported data related to possible longer-term “programmed”
metabolic or physiological consequences of multi-nutrient sup-
plementation in early infancy.
Meta-analysis of data from trials that included a control group
without bone mineral supplementation showed that multi-nutri-
ent fortiﬁcation reduces serum alkaline phosphatase (ALP) levels
but provided limited evidence of effects on other measures of bone
mineralisation or health. This review found no consistent evidence
of other potential beneﬁts or harms of fortiﬁcation, including no
data to suggest that fortiﬁcation increases the risk of feed intoler-
ance or necrotising enterocolitis in preterm infants.
Overall completeness and applicability of
evidence
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We recommend cautious interpretation and application of these
ﬁndings. Althoughmeta-analyses indicate that multi-nutrient for-
tiﬁcation increases rates of growth, typical effect sizes are verymod-
est. Over the course of four weeks, multi-nutrient fortiﬁcation for
a very preterm infant weighing 1 kg at birth would result in an
extra 50 g of weight gain, 7 mm of length gain and 3 mm of head
circumference gain. As well as uncertainty about the clinical im-
portance of these small effects on hospital growth rates, consid-
erable uncertainty remains about longer-term impact on growth
or development. Similarly, although multi-nutrient fortiﬁcation
that includes minerals (vs breast milk without added minerals) re-
duces the serum ALP level, this in itself is an insensitive measure
of bone mineralisation or health (Tinnion 2012). Furthermore, in
current clinical practice, mineral supplements (mainly phosphate)
are available for infants at high risk of, or with biochemical or
other features of, metabolic bone disease.
Meta-analyses of growth outcomes showed substantial statistical
heterogeneity that was not explained by major differences in trial
design or conduct. Participants in these trials were similar (mostly
stable VLBW infants). Although we noted some variation in types
of fortiﬁer used, the overall target level of multi-nutrient fortiﬁ-
cation was similar. Most trials aimed to provide extra energy, pro-
tein and minerals by adding a powdered, commercially available
multi-nutrient fortiﬁer to breast milk to attain 75 to 80 kcal/100
mL and about 2.0 to 2.6 g of protein/100 mL (plus proportionate
supplements of minerals, vitamins and trace elements). This ap-
proach maintained optimal protein-to-energy ratios to ensure that
the protein contributed to growth and was not catabolised as a
fuel source (Kashyap 1994). However, these total levels of protein
and energy fortiﬁcation are at the lower bounds of current rec-
ommended intakes needed to match intrauterine accretion (based
on receiving about 150 mL/kg/d of milk), and this is a likely ex-
planation for the limited impact of the intervention on growth
parameters. These ﬁndings are broadly consistent with those of
another Cochrane review which found that formula-fed preterm
infants who received higher levels of protein (> 3 g/kg/d) gained
weight about 2.4 g/kg/d faster than infants who received standard
levels of protein (Fenton 2014).
A ﬁnal major limitation of this review is that most included tri-
als were undertaken at healthcare facilities in high-income coun-
tries, and none in community settings or low-income countries.
Reported evidence therefore may be of limited use to inform care
practice in the resource-limited settings where most preterm and
low birth weight infants are cared for globally (Imdad 2013).
Quality of the evidence
We assessed the quality of the evidence as low or moderate for
most outcomes (Summary of ﬁndings for the main comparison).
Included trials were small and were generally of low methodolog-
ical quality, yielding no evidence of use of adequate measures to
conceal random allocation and incomplete follow-up assessment
during the intervention period. Blinding of participants and care-
givers was not possible given the nature of the intervention, but
this is not likely to be a major source of bias in growth assess-
ments. Knowledge of the intervention group may have affected
caregivers’ or mothers’ perceptions and views of feeding, and may
have inﬂuenced decisions on whether any formula should be given
as a supplement to (or instead of ) breast milk. These trials did not
examine whethermulti-nutrient fortiﬁcation affected themother’s
commitment to establish breast feeding, or whether differences
were noted in the proportion of infants receiving any breast milk
at the end of the intervention period.
Potential biases in the review process
Our main concern with the review process is the possibility that
ﬁndings are subject to publication and other reporting biases. We
attempted tominimise this threat by screening the reference lists of
included trials and related reviews and searching the proceedings of
major international perinatal conferences to identify trial reports
that are not (or are not yet) published in full form in academic
journals. The meta-analyses that we performed did not contain
sufﬁcient trials to explore symmetry of funnel plots as a means of
identifying possible publication or reporting bias.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Multi-nutrient fortiﬁcation of human milk is associated with
small, short-term increases in weight gain and in linear and head
growth.No evidence suggests that these short-termgains in growth
lead to any long-term effects on growth or development. Investi-
gators reported no increase in adverse effects among infants who
received multi-nutrient fortiﬁers, although the total number of
infants studied was small and the data that could be abstracted
from published studies were limited.
Implications for research
Given the potential for multi-nutrient fortiﬁcation of breast milk
to affect important outcomes in preterm infants, this interven-
tion merits further assessment. As this practice is already widely
established and accepted as a standard of care in many neonatal
units, it is important for researchers to determine whether moth-
ers and clinicians would support a trial of this intervention. All
trials should be powered to detect potentially important effects
on growth rates, as well as potential adverse consequences, during
infancy and beyond. Trials should attempt to ensure that care-
givers and assessors are blind to the intervention. Although this
goal is more easily achievable for longer-term assessments, it is
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also important for ascertainment of adverse events, such as feed-
ing intolerance and necrotising enterocolitis, when the threshold
for investigation or diagnosis may be affected by knowledge of
the intervention. We have identiﬁed one such planned trial (Mills
2015).
New research areas
Most commercially available fortiﬁers contain varying amounts of
protein, carbohydrate, calcium, phosphate, other minerals (zinc,
manganese, magnesium and copper), vitamins and electrolytes.
Investigators have not evaluated the beneﬁts of many of these in-
dividual components in a controlled manner. In the future, re-
searchers could compare different proprietary preparations to eval-
uate both short-term and long-term outcomes and adverse effects,
while searching for the “optimal” composition of fortiﬁers. Inves-
tigators could also examine the effects of targeted or adjustable for-
tiﬁcation to determine whether human milk-based fortiﬁer pro-
vides any (cost-effective) advantages over cow’s milk-based forti-
ﬁer.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bhat 2003
Methods Randomised controlled trial
Participants 100 VLBW infants
Excusion criterion: need for prolonged mechanical ventilation
Setting: Special Care Baby Unit, Khoula Hospital, Muscat, Oman
Interventions Intervention (N = 50): fortiﬁed human milk (4 g of powdered fortiﬁer to achieve 81
kcal, 2.4 g protein, 9.0 g carbohydrates per 100 mL of milk)
Control (N = 50): human milk only
If amounts were insufﬁcient, human milk was supplemented with formula up to a
maximum of 15% of energy for 2 days. Babies who required supplementation beyond
this were excluded from the study
Outcomes • Weight gain
• Markers of nutritional and bone mineral status
• Adverse events including necrotising enterocolitis
Notes Human milk was enriched with a fortiﬁer after babies reached a volume of 140 mL/kg/
d by the enteral route
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Report states that infants were “randomly assigned”, but
method of sequence generation not described
Allocation concealment (selection bias) Unclear risk No details reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study was described as “double-blind”, but it was not
speciﬁed who was blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Study was described as “double-blind”, but it was not
speciﬁed who was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Nodetails of infants lost to follow-upwere reported. Lack
of attrition bias was assumed
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Faerk 2000
Methods Randomised controlled trial
Participants 103 very preterm infants
Excusion criterion: major congenital anomaly
Setting: NICUs, Rigshospitalet and Hvidovre Hospital, Copenhagen, Denmark
Interventions Intervention (N = 51): human milk (maternal or donor) supplemented with 0.4 g
protein, 1.4 g carbohydrate, 35 mg calcium and 17 mg phosphorus per 100 mL (Milupa
Eoprotin)
Control (N = 52): maternal or donor milk supplemented with 10 mg phosphate per 100
mL
Outcomes • Weight, length and head circumference at term
• Measures of bone mineralisation (DEXA scan)
• Necrotising enterocolitis
Notes Target intake of 200 mL/kg/d
All infants received vitamin D 800 IU per day
Intervention ceased when breast-fed or at 36 weeks’ postmenstrual age
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of sequence generation not described
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study is described as “double-blind”, but it was not spec-
iﬁed who was blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Study is described as “double-blind”, but it was not spec-
iﬁed who was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 103 infants were randomised, but outcome data were re-
ported for only 76 (74%) because of loss to follow-up or
technical problems with DEXA scans. Further informa-
tion about outcomes was not available from investigators
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Gathwala 2012
Methods Randomised controlled trial
Participants 67 consecutive preterm infants of birth weight < 1800 g
Eligibility criteria: healthy preterm infants, appropriate for gestational age, no birth
asphyxia, enterally fed with breast milk by 14 days of life, no congenital malformations,
no ventilatory support previous 7 days, no diuretic or steroid therapy
Setting: Neonatology Unit, Department of Paediatrics, Pt. B.D. Sharma PGIMS, Ro-
htak, India
Interventions Intervention (N = 34): breast milk fortiﬁed with Lactodex Human Milk Fortiﬁer (to
achieve 80 kcal, 9.4 g carbohydrate, 2.2 g protein per 100 mL, plus minerals and elec-
trolytes)
Control (N = 33): unfortiﬁed breast milk
Infants were excluded from the study if they needed more than 25% of their daily
requirements to be provided by formula or other milk
Outcomes • Time to regain birth weight
• Time to reach 2200 g
• Duration of hospital stay
• Biochemical markers of nutritional status (including serum ALP)
Notes Incidence of feed intolerance or necrotising enterocolitis not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Use of a random numbers table
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk It was not reported whether personnel were blinded (par-
ticipant blinding irrelevant in this context)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It was not reported whether outcome assessors were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Four babies in the intervention group and 3 in the control
group were excluded post randomisation, as their need
for additional milk exceeded 25%. These infants were
not included in intention-to-treat analyses
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Gross 1987 (1)
Methods Randomised controlled trial (2-phase trial, referred to as Gross 1987 (1) and Gross 1987
(2))
Participants 20 infants with birth weight < 1600 g
Eligibility criteria: birth weight appropriate for gestational age, free from congenital
anomaly or major disease, breathing room air, ability to begin enteral feeding within ﬁrst
week after birth
Setting: Duke University Medical Center, Durham, North Carolina, USA
Interventions Intervention (N = 10): humanmilkmixed with premature infant formula Similac Special
Care (Ross Laboratories) containing 1.8 g protein per 100 mL, as well as carbohydrate
Control (N = 10): human milk with no supplementation
Feeding of human milk supplemented with formula commenced after 1 week of enteral
feeds of unfortiﬁedhumanmilk. All infants received intravenous dextrose and electrolytes
until day 5 of feeding. All infants received supplemental vitamins with their milk from
day 8 of feeding
Outcomes • In-hospital growth parameters
• Growth at 44 weeks’ postmenstrual age
• Bone mineral content and biochemical indices of bone metabolism
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Details of sequence generation not re-
ported. Report states that infants were “as-
signed randomly” to receive fortiﬁed or un-
fortiﬁed breast milk
Allocation concealment (selection bias) Unclear risk Report states that “sealed envelopes” were
used, but it is unclear whether these were
sequentially numbered and opaque
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk It was not reported whether personnel were
blinded (participant blinding irrelevant in
this context)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It was not reported whether outcome asses-
sors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No details of infants lost to follow-up were
reported. Lack of attritionbiaswas assumed
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Gross 1987 (2)
Methods Randomised controlled trial (2-phase trial, referred to as Gross 1987 (1) and Gross 1987
(2))
Participants 30 infants with birth weight < 1600 g
Eligibility criteria: birth weight appropriate for gestational age, free from congenital
anomaly or major disease, breathing room air, ability to begin enteral feeding within ﬁrst
week after birth
Setting: Boston Perinatal Center, Boston, Massachusetts, USA
Interventions Intervention 1 (N = 11): human milk mixed with premature infant formula Similac
Special Care (Ross Laboratories) containing 1.8 g protein per 100 mL, as well as carbo-
hydrate (as above for Gross 1987 (1))
Intervention 2 (N = 10): human milk mixed with powdered breast milk fortiﬁer
Control (N = 9): human milk with no supplementation
Fortiﬁcation with the powdered fortiﬁer was introduced after 2 weeks of enteral feeds of
unfortiﬁed human milk. All infants received intravenous dextrose and electrolytes until
day 5 of feeding. All infants received supplemental vitamins with their milk from day
8 of feeding. For this review, participants from the 2 intervention groups were taken
together as infants receiving fortiﬁcation
Outcomes • In-hospital growth parameters
• Growth at 44 weeks’ postmenstrual age
• Bone mineral content and biochemical indices of bone metabolism
Notes The full composition of powdered fortiﬁer was not reported in the paper. Following
our own Internet research, we deemed it appropriate for inclusion, as powdered fortiﬁer
appeared to include protein and energy, as required by our inclusion criteria
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Details of sequence generation not re-
ported. Report states that infants were “as-
signed randomly” to receive fortiﬁed or un-
fortiﬁed breast milk
Allocation concealment (selection bias) Unclear risk Report states that “sealed envelopes” were
used, but it is unclear whether these were
sequentially numbered and opaque
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk It was not reported whether personnel were
blinded (participant blinding irrelevant in
this context)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It was not reported whether outcome asses-
sors were blinded
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Gross 1987 (2) (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Four infants (2 in intervention group1, and
2 in intervention group 2) did not com-
plete the study because of feed intolerance.
Results of growth outcomes for these in-
fants were not presented
Lucas 1996
Methods Randomised controlled trial
Participants 275 preterm infants with birth weight < 1850 g
Eligibility criteria: no major congenital abnormalities, resident in UK, mother agreed to
provide breast milk
Setting: 2 centres in Cambridge and Norwich, UK
Interventions Intervention (N = 137): maternal milk supplemented with (per 100 mL) 0.7 g protein
(bovine), 2.73 g carbohydrate, 0.05 g fat, 90 mg calcium and 45 mg phosphate, as well
as electrolytes (Enfamil, Mead Johnson)
Control (N = 138): maternal milk supplemented with 15 mg/100 mL phosphate
Enteral intake 180 mL/kg/d
Intervention ceased at discharge, or when weight reached 2000 g
All infants received vitamins (including vitamin D 260 IU/100 mL)
Infants whose mothers could not provide sufﬁcient milk were supplemented with a
preterm formula and were not excluded from the analysis
Outcomes • In-hospital growth rates
• Growth to 9 and 18 months
• Neurodevelopmental outcomes at 9 and 18 months
• Serum indices of bone metabolism
• Necrotising enterocolitis
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Use of permuted blocks of randomised length
Allocation concealment (selection bias) Low risk Use of sealed opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded
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Lucas 1996 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded (except for assessment of neurodevelopmental
outcomes)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Nodetails of infants lost to follow-upwere reported. Lack
of attrition bias was assumed
Modanlou 1986
Methods Randomised controlled trial
Participants 39 infants of birth weight between 1000 and 1500 g
Eligibility criteria: birth weight appropriate for gestational age, no ventilatory assistance
after 7 days, no supplemental oxygen after 10 days, fewer than 3 days of diuretic therapy,
enteral feeding by 14 days after birth
Setting: Miller Children’s Hospital of Long Beach, California, USA
Interventions Intervention (N = 20): mother’s own milk plus fortiﬁer (to provide supplemental 0.7 g
protein, 2.7 g carbohydrate, “trace” fat, 60 mg calcium and 33 mg phosphate per 100
mL of breast milk)
Control (N = 19): mother’s own milk
Formula and human milk were diluted initially and the fortiﬁer added gradually to
milk for infants in the intervention group to reach target caloriﬁc density over 7 days
(approximately) in all groups. Milk was generally provided by intermittent bolus gavage
until nipple feedings were tolerated. Infants received standard infant formula if their
mother’s milk was unavailable for “an occasional feeding” (up to a maximum of 10% of
feedings per week)
Outcomes • Growth rates (weight, length, head circumference)
• Feeding intolerance and necrotising enterocolitis
• Biochemical status
• Bone mineral content
Notes Intervention ceased at discharge, or when weight reached 1800 g
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Report states that infants were “randomly assigned”, but
method of sequence generation was not described
Allocation concealment (selection bias) Unclear risk Report states that sealed envelopes were used. It is not
reported whether these were sequentially numbered and
opaque
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Modanlou 1986 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 19 infants left the study after randomisation because of
“insufﬁcient maternal milk supply”, and another 2 in-
fants were withdrawn because of suspected NEC. Out-
come data for inclusion in intention-to-treat analyses
were not available for these infants
Mukhopadhyay 2007
Methods Randomised controlled trial
Participants 166 VLBW infants (and gestational age < 35 weeks at birth)
Eligibility criteria: feed volume of 150 mL/kg/d, feeds consisting of at least 80% breast
milk, no congenital malformations nor gastrointestinal abnormalities
Setting: PGIMER, Chandigarh, India
Interventions Intervention (N = 85): breast milk fortiﬁed with Lactodex Human Milk Fortiﬁer (2 g
sachet per 50 mL of milk: 0.2 g protein, 1.2 g carbohydrate, 6.5 kcal energy)
Control (N = 81): breast milk with added vitamins and minerals
Outcomes • Growth rates (weight, length, head circumference)
• Biochemical parameters
• Length of hospital stay
• Feeding intolerance and necrotising enterocolitis
Notes Fortiﬁcation was stopped once babies reached a weight of 2000 g or were fully breast-
fed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Use of a random numbers table
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk It was not reported whether personnel were blinded (par-
ticipant blinding irrelevant in this context)
31Multi-nutrient fortification of human milk for preterm infants (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mukhopadhyay 2007 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It was not reported whether outcome assessors were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Nodetails of infants lost to follow-upwere reported. Lack
of attrition bias was assumed
Nicholl 1999
Methods Randomised controlled trial
Participants 23 VLBW infants receiving enteral feeds of at least 150 mL/kg/d
Eligibility criteria: no ﬂuid restriction, no diuretics, no postnatal systemic steroid use,
no signiﬁcant congenital abnormality
Setting: neonatal intensive care unit, Kings College Hospital, London, UK
Interventions Intervention (N = 13): maternal (or pasteurised pooled donor milk) supplemented (per
100 mL) with 0.7 g protein, 2.0 g carbohydrate, 30 mg calcium, 40 mg phosphorus,
trace minerals and vitamins
Control (N = 10): unsupplemented maternal or donor milk
Intervention ceased when infants no longer required nasogastric feeds
Outcomes • In-hospital growth parameters
• Indices of bone metabolism
Notes Intervention ceased when infants no longer required nasogastric feeds
One infant whose mother declined fortiﬁer was included in results of non-fortiﬁed
infants, and one baby whose mother preferred the addition of fortiﬁer was included in
results of the intervention group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Report states that infants were “randomized”, but
method of sequence generation was not described
Allocation concealment (selection bias) Low risk Sealed opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded
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Nicholl 1999 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Nodetails of infants lost to follow-upwere reported. Lack
of attrition bias was assumed
Pettifor 1989
Methods Randomised controlled trial
Participants 100 consecutive infants weighing between 1000 and 1500 g at birth
Eligibility criteria: no major congenital abnormalities or metabolic disturbances, no
requirement for ventilation at the point of entry into the study (day 4 after birth), free
from serious infection, receiving at least 45 mL/kg/d of gavage feedings (expressed breast
milk) at the beginning of the study
Setting: Baragwanath Hospital, Bertsham, South Africa
Interventions Intervention (N = 53): mother’s own milk supplemented with (per 100 mL) 0.05 g
protein, 1.1 g carbohydrate, 0.26 g fat, 72.3 mg calcium and 34 mg phosphate, along
with electrolytes and vitamins (HMF, Ross Laboratories)
Control (N = 47): mother’s own milk
Feeds were titrated as tolerated up to 200 mL/kg/d. Feeds were delivered by nasogastric
tube until infants weighed 1600 g. At this point, bottle feeding was introduced gradually.
Infants were removed from the study if their mother could not supply sufﬁcient breast
milk
Outcomes • Weight gain
• Serum calcium, phosphorus, alkaline phosphatase and albumin levels
• Bone mineral homeostasis
• Necrotising enterocolitis (data obtained from trial investigators)
Notes 41 infants left the study after randomisation for various reasons (insufﬁcient maternal
milk supply, death, reduced enteral intake for > 72 hours, incomplete data). Data for
these infants were not included in intention-to-treat analyses of growth outcomes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Report states that infants were “randomly assigned”, but
method of sequence generation was not described
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk It was not reported whether personnel were blinded (par-
ticipant blinding irrelevant in this context)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It was not reported whether outcome assessors were
blinded
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Pettifor 1989 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 41 (of 100) infants left the study after randomisation for
various reasons (insufﬁcient maternal milk supply, death,
reduced enteral intake for > 72 hours, incomplete data)
. These infants were not included in intention-to-treat
analyses of growth outcomes
Polberger 1989
Methods Randomised controlled trial
Participants 34 VLBW infants
Eligibility criteria: birth weight appropriate for gestational age, tolerance of complete
enteral feeding (170 mL/kg/d), no obvious disease or major malformations, no supple-
mental oxygen therapy
Setting: 2 neonatal units in Lund and Malmö, Sweden
Interventions Intervention (N = 7): maternal or donor milk supplemented with (per 100 mL) 1.0 g
human milk protein and 1.0 g human milk fat
Control 1 (N = 7): maternal or donor milk with no fortiﬁcation
Feeds of 170 mL/kg/d were given throughout the study. When mother’s own milk was
insufﬁcient, mature human milk from a milk bank was used. All infants, regardless of
group allocation, received enteral supplementation with vitamin E, folic acid, a multi-
vitamin preparation and additional vitaminD. They also received one-off administration
of calcium and phosphate, and from 4 weeks of age, elemental iron was given
Outcomes • Growth parameters
Notes Six infants left the study after randomisation for various reasons (apnoea, intolerance to
the ﬁxed feed volume, need for intravenous therapy). These infants were not included
in intention-to-treat analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Report states that infants were “randomly assigned”, but
method of sequence generation was not described
Allocation concealment (selection bias) Unclear risk Report states that “closed envelopes” were used, but it is
not speciﬁed whether these were sequentially numbered,
opaque and sealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study is described as “double-blind”, but it was not spec-
iﬁed who was blinded
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Polberger 1989 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Study is described as “double-blind”, but it was not spec-
iﬁed who was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Several (up to 6, but exact number unclear) infants were
excluded from the study after randomisation. Intention-
to-treat analyses were not reported
Porcelli 1992
Methods Randomised controlled trial
Participants 20 preterm infants with birth weight between 1110 and 2000 g
Eligibility criteria: none reported
Setting: Pediatric Hospital “V. Buzzi”, Milano, Italy
Interventions Intervention (N = 10): human milk fortiﬁed with FM85 Nestlè (including energy and
protein)
Control 1 (N =10): human milk with no fortiﬁcation
All infants received supplemental vitamin D
Outcomes • Growth parameters
• Metabolic parameters
• Measures of bone mineralisation
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Report states that infants were “randomized”, but
method of sequence generation was not described
Allocation concealment (selection bias) Unclear risk Details of allocation concealment were not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk It was not reported whether personnel were blinded (par-
ticipant blinding irrelevant in this context)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It was not reported whether outcome assessors were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Nodetails of infants lost to follow-upwere reported. Lack
of attrition bias was assumed
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Wauben 1998
Methods Randomised controlled trial
Participants 31 preterm infants of birth weight < 1800 g
Eligibility criteria: older than 1 week of age (birth weight appropriate for gestational age),
consumption of full oral feeds (enteral intake 160mL/kg/d) for longer than 5 days, stable
weight gain greater than 10 g/kg/d, no severe congenital malformations/chromosomal
abnormalities, no gastrointestinal disease
Setting: Neonatal Units of the Children’s Hospitals of the Hamilton Health Sciences
Corporation and St Joseph’s Hospitals, Hamilton, Ontario, Canada
Interventions Intervention (N = 15): maternal milk fortiﬁed with (per 100 mL) 0.37 g human milk
protein, 3.47 g carbohydrate, 61 mg calcium, 44 mg phosphorus, electrolytes and other
minerals and vitamins (including vitamin D 472 IU/d) (Wyeth-Ayerst, Toronto, On-
tario, Canada) (fortiﬁcation commenced when maternal milk contributed > 80% of
infant’s enteral intake)
Control (N = 16): maternal milk supplemented with calcium glycerophosphate
Outcomes • Short-term growth
• Biochemical indices of bone metabolism
• Bone mineral content
Notes Supplementation in both groups was increased gradually until a target amount was
reached. Intervention ceased at discharge or at 38 weeks’ postmenstrual age, whichever
occurred later
Infants in the control arm were signiﬁcantly lighter at birth and were signiﬁcantly lighter
and shorter at study entry than infants in the group receiving HMF
Nutrient intakes were measured: mean ﬂuid intakes signiﬁcantly greater in the control
group (177 vs 164 mL/kg/d)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers table
Allocation concealment (selection bias) Unclear risk Details of allocation concealment were not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Six infants (3 in each group)were excluded from the study
after randomisation. Details were reported, and no bias
was apparent between groups. Intention-to-treat analyses
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Wauben 1998 (Continued)
of growth outcomes data were not reported
Zuckerman 1994
Methods Quasi-randomised controlled trial
Participants 56 infants with birth weight < 1200 g, older than 2 weeks of age
Eligibility criteria: no congenital abnormalities, infections, nor disorders causing bone
disease
Setting: Baragwanath Hospital, Bertsham, South Africa
Interventions Intervention (N = 29): maternal milk mixed in equal proportions with premature infant
formula (Alprem, Nestle) to yield supplements (per 100 mL) of fat, carbohydrate and
calcium 14.5 mg, phosphate 7 mg and protein 0.6 g
Control (N = 27): unsupplemented human milk
Outcomes • In-hospital growth rates
• Serum indices of bone metabolism
• Radiographic changes of metabolic bone disease
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Infants were assigned to the 2 groups according to
their hospital number (odd or even)
Allocation concealment (selection bias) High risk Infants were assigned to the 2 groups according to
their hospital number (odd or even)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unblinded (radiographers were reported to have
been blinded)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Three infants in the control group were excluded
because of incorrect feeding
ALP - alkaline phosphatase
DEXA - dual-energy x-ray absorptiometry
NEC - necrotising enterocolitis
NICU - neonatal intensive care unit
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VLBW - very low birth weight
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abrams 2014 Comparison of human milk-based vs cow’s milk-based protein fortiﬁcation
Arslanoglu 2009 Comparison of different fortiﬁcation regimens, with no control group receiving unfortiﬁed milk
Carey 1987 Fortiﬁcation with protein only; no fortiﬁcation with energy
Greer 1988 Fortiﬁcation with protein only; no fortiﬁcation with energy
Hair 2014 Control group received fortiﬁed milk
Kashyap 1990 Fortiﬁcation with protein only; no fortiﬁcation with energy
Reali 2010 Literature review
Tarcan 2004 Not a randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
Mills 2015
Trial name or title PREterM FOrmula Or Donor Breast Milk for Premature Babies (PREMFOOD)
Methods Open, 3-arm randomised controlled feasibility trial
Participants Neonates at < 30 weeks’ gestation; babies with conditions that preclude enteral feeding or are immediately
life-limiting are ineligible
Interventions Participants will be randomised to receive fortiﬁed donor breast milk (DBM), unfortiﬁed DBM or preterm
formula to make up any shortfall in maternal breast milk until 35 weeks’ postmenstrual age, with a sample
size of 22 in each group
Outcomes Primary outcome measure: total body adiposity (measured as close as possible to the baby’s due date, at an
average age of 10 weeks (range 8 to 15 weeks))
Starting date 2015
Contact information Prof. Neena Modi, Section of Neonatal Medicine, Imperial College London, London, UK; Department of
Neonatal Medicine, Chelsea and Westminster Hospital, London, UK
Notes Feasibility trial
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D A T A A N D A N A L Y S E S
Comparison 1. Fortified breast milk versus unfortified breast milk
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Weight gain (g/kg/d) 10 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 All trials 10 635 Mean Difference (IV, Fixed, 95% CI) 1.81 [1.23, 2.40]
1.2 Trials recruiting only very
preterm or VLBW infants
5 269 Mean Difference (IV, Fixed, 95% CI) 2.82 [1.83, 3.80]
1.3 Trials conducted in low-
or middle-income countries
2 214 Mean Difference (IV, Fixed, 95% CI) 1.86 [0.70, 3.01]
2 Length gain (cm/wk) 8 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 All trials 8 555 Mean Difference (IV, Fixed, 95% CI) 0.12 [0.07, 0.17]
2.2 Trials recruiting only very
preterm or VLBW infants
3 189 Mean Difference (IV, Fixed, 95% CI) 0.21 [0.14, 0.28]
2.3 Trials conducted in low-
or middle-income countries
1 157 Mean Difference (IV, Fixed, 95% CI) 0.18 [0.10, 0.26]
3 Head growth (cm/wk) 8 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 All trials 8 555 Mean Difference (IV, Fixed, 95% CI) 0.08 [0.04, 0.12]
3.2 Trials recruiting only very
preterm or VLBW infants
3 189 Mean Difference (IV, Fixed, 95% CI) 0.11 [0.05, 0.17]
3.3 Trials conducted in low-
or middle-income countries
1 157 Mean Difference (IV, Fixed, 95% CI) 0.08 [0.02, 0.14]
4 Weight at 12 to 18 months (kg) 2 270 Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.31, 0.25]
5 Length at 12 to 18 months (cm) 2 270 Mean Difference (IV, Fixed, 95% CI) -0.19 [-0.98, 0.60]
6 Head circumference at 12 to 18
months (cm)
2 270 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.37, 0.18]
7 Mental development index at 18
months
1 245 Mean Difference (IV, Fixed, 95% CI) 2.20 [-3.35, 7.75]
8 Psychomotor development index
at 18 months
1 245 Mean Difference (IV, Fixed, 95% CI) 2.40 [-1.90, 6.70]
9 Length of hospital stay (weeks) 2 210 Mean Difference (IV, Fixed, 95% CI) 0.38 [-0.16, 0.93]
9.1 All trials 2 210 Mean Difference (IV, Fixed, 95% CI) 0.38 [-0.16, 0.93]
10 Feed intolerance 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 All trials 5 255 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.54, 1.49]
10.2 Trials recruiting only
very preterm or VLBW infants
2 174 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.42, 1.22]
10.3 Trials conducted in low-
or middle-income countries
1 157 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.41, 1.23]
11 Necrotising enterocolitis 11 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 All trials 11 882 Risk Ratio (M-H, Fixed, 95% CI) 1.57 [0.76, 3.23]
11.2 Trials recruiting only
very preterm or VLBW infants
7 539 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.49, 2.88]
11.3 Trials conducted in low-
or middle-income countries
3 310 Risk Ratio (M-H, Fixed, 95% CI) 1.73 [0.33, 9.11]
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12 Serum ALP (IU/L): restricted
to trials without mineral
supplementation of the control
group
5 Mean Difference (IV, Fixed, 95% CI) Subtotals only
12.1 All trials 5 325 Mean Difference (IV, Fixed, 95% CI) -126.36 [-190.89, -
61.83]
12.2 Trials recruiting only
very preterm or VLBW infants
4 265 Mean Difference (IV, Fixed, 95% CI) -132.03 [-198.09, -
65.98]
12.3 Trials conducted in low-
or middle-income countries
4 309 Mean Difference (IV, Fixed, 95% CI) -119.66 [-185.54, -
53.78]
13 Bone mineral content (mg/cm):
restricted to trials without
mineral supplementation of the
control group
1 59 Mean Difference (IV, Fixed, 95% CI) 12.00 [6.28, 17.72]
Analysis 1.1. Comparison 1 Fortified breast milk versus unfortified breast milk, Outcome 1 Weight gain
(g/kg/d).
Review: Multi-nutrient fortiﬁcation of human milk for preterm infants
Comparison: 1 Fortiﬁed breast milk versus unfortiﬁed breast milk
Outcome: 1 Weight gain (g/kg/d)
Study or subgroup Fortiﬁed Unfortiﬁed
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 All trials
Modanlou 1986 8 26.7 (3.4) 10 19.4 (2.7) 4.0 % 7.30 [ 4.41, 10.19 ]
Gross 1987 (1) 10 19.9 (2.5) 10 17.7 (4.4) 3.4 % 2.20 [ -0.94, 5.34 ]
Gross 1987 (2) 17 21.5 (3.5) 9 17.5 (3.3) 4.6 % 4.00 [ 1.28, 6.72 ]
Polberger 1989 7 20.4 (2.8) 7 15.3 (3.2) 3.4 % 5.10 [ 1.95, 8.25 ]
Pettifor 1989 29 16.7 (5) 28 16.8 (6.4) 3.8 % -0.10 [ -3.09, 2.89 ]
Porcelli 1992 10 11.4 (2.7) 10 12 (3) 5.4 % -0.60 [ -3.10, 1.90 ]
Lucas 1996 137 15.6 (4.7) 138 15 (3.5) 35.2 % 0.60 [ -0.38, 1.58 ]
Wauben 1998 12 16.6 (1.6) 13 14.2 (2) 16.9 % 2.40 [ 0.99, 3.81 ]
Nicholl 1999 13 15.1 (3.3) 10 13.2 (6.4) 1.8 % 1.90 [ -2.45, 6.25 ]
Mukhopadhyay 2007 82 15.1 (4) 75 12.9 (4) 21.5 % 2.20 [ 0.95, 3.45 ]
Subtotal (95% CI) 325 310 100.0 % 1.81 [ 1.23, 2.40 ]
Heterogeneity: Chi2 = 32.63, df = 9 (P = 0.00015); I2 =72%
Test for overall effect: Z = 6.12 (P < 0.00001)
-10 -5 0 5 10
Favours control Favours fortiﬁed
(Continued . . . )
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(. . . Continued)
Study or subgroup Fortiﬁed Unfortiﬁed
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
2 Trials recruiting only very preterm or VLBW infants
Modanlou 1986 8 26.7 (3.4) 10 19.4 (2.7) 11.7 % 7.30 [ 4.41, 10.19 ]
Pettifor 1989 29 16.7 (5) 28 16.8 (6.4) 10.9 % -0.10 [ -3.09, 2.89 ]
Polberger 1989 7 20.4 (2.8) 7 15.3 (3.2) 9.9 % 5.10 [ 1.95, 8.25 ]
Nicholl 1999 13 15.1 (3.3) 10 13.2 (6.4) 5.2 % 1.90 [ -2.45, 6.25 ]
Mukhopadhyay 2007 82 15.1 (4) 75 12.9 (4) 62.3 % 2.20 [ 0.95, 3.45 ]
Subtotal (95% CI) 139 130 100.0 % 2.82 [ 1.83, 3.80 ]
Heterogeneity: Chi2 = 16.02, df = 4 (P = 0.003); I2 =75%
Test for overall effect: Z = 5.58 (P < 0.00001)
3 Trials conducted in low- or middle-income countries
Pettifor 1989 29 16.7 (5) 28 16.8 (6.4) 14.9 % -0.10 [ -3.09, 2.89 ]
Mukhopadhyay 2007 82 15.1 (4) 75 12.9 (4) 85.1 % 2.20 [ 0.95, 3.45 ]
Subtotal (95% CI) 111 103 100.0 % 1.86 [ 0.70, 3.01 ]
Heterogeneity: Chi2 = 1.94, df = 1 (P = 0.16); I2 =48%
Test for overall effect: Z = 3.15 (P = 0.0016)
Test for subgroup differences: Chi2 = 3.04, df = 2 (P = 0.22), I2 =34%
-10 -5 0 5 10
Favours control Favours fortiﬁed
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Analysis 1.2. Comparison 1 Fortified breast milk versus unfortified breast milk, Outcome 2 Length gain
(cm/wk).
Review: Multi-nutrient fortiﬁcation of human milk for preterm infants
Comparison: 1 Fortiﬁed breast milk versus unfortiﬁed breast milk
Outcome: 2 Length gain (cm/wk)
Study or subgroup Fortiﬁed Unfortiﬁed
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 All trials
Modanlou 1986 8 0.99 (0.4) 10 0.81 (0.44) 1.6 % 0.18 [ -0.21, 0.57 ]
Gross 1987 (1) 10 0.89 (0.19) 10 0.81 (0.22) 7.3 % 0.08 [ -0.10, 0.26 ]
Gross 1987 (2) 17 0.84 (0.25) 9 0.79 (0.12) 11.8 % 0.05 [ -0.09, 0.19 ]
Polberger 1989 7 1.2 (0.17) 7 0.83 (0.17) 7.5 % 0.37 [ 0.19, 0.55 ]
Porcelli 1992 10 0.6 (0.2) 10 0.7 (0.3) 4.8 % -0.10 [ -0.32, 0.12 ]
Lucas 1996 137 0.93 (0.47) 138 0.96 (0.47) 19.3 % -0.03 [ -0.14, 0.08 ]
Wauben 1998 12 1.1 (0.2) 13 0.9 (0.2) 9.7 % 0.20 [ 0.04, 0.36 ]
Mukhopadhyay 2007 82 1.04 (0.3) 75 0.86 (0.2) 38.0 % 0.18 [ 0.10, 0.26 ]
Subtotal (95% CI) 283 272 100.0 % 0.12 [ 0.07, 0.17 ]
Heterogeneity: Chi2 = 22.71, df = 7 (P = 0.002); I2 =69%
Test for overall effect: Z = 4.80 (P < 0.00001)
2 Trials recruiting only very preterm or VLBW infants
Modanlou 1986 8 0.99 (0.4) 10 0.81 (0.44) 3.3 % 0.18 [ -0.21, 0.57 ]
Polberger 1989 7 1.2 (0.17) 7 0.83 (0.17) 15.9 % 0.37 [ 0.19, 0.55 ]
Mukhopadhyay 2007 82 1.04 (0.3) 75 0.86 (0.2) 80.7 % 0.18 [ 0.10, 0.26 ]
Subtotal (95% CI) 97 92 100.0 % 0.21 [ 0.14, 0.28 ]
Heterogeneity: Chi2 = 3.67, df = 2 (P = 0.16); I2 =46%
Test for overall effect: Z = 5.80 (P < 0.00001)
3 Trials conducted in low- or middle-income countries
Mukhopadhyay 2007 82 1.04 (0.3) 75 0.86 (0.2) 100.0 % 0.18 [ 0.10, 0.26 ]
Subtotal (95% CI) 82 75 100.0 % 0.18 [ 0.10, 0.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.46 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.72, df = 2 (P = 0.09), I2 =58%
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Analysis 1.3. Comparison 1 Fortified breast milk versus unfortified breast milk, Outcome 3 Head growth
(cm/wk).
Review: Multi-nutrient fortiﬁcation of human milk for preterm infants
Comparison: 1 Fortiﬁed breast milk versus unfortiﬁed breast milk
Outcome: 3 Head growth (cm/wk)
Study or subgroup Fortiﬁed Unfortiﬁed
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 All trials
Modanlou 1986 8 1.09 (0.07) 10 0.82 (0.24) 6.2 % 0.27 [ 0.11, 0.43 ]
Gross 1987 (1) 10 0.92 (0.09) 10 0.83 (0.16) 11.7 % 0.09 [ -0.02, 0.20 ]
Gross 1987 (2) 17 0.84 (0.21) 9 0.84 (0.09) 11.3 % 0.0 [ -0.12, 0.12 ]
Polberger 1989 7 1.11 (0.13) 7 0.94 (0.25) 3.5 % 0.17 [ -0.04, 0.38 ]
Porcelli 1992 10 0.7 (0.3) 10 0.7 (0.2) 3.0 % 0.0 [ -0.22, 0.22 ]
Lucas 1996 137 1.01 (0.47) 138 0.95 (0.35) 15.7 % 0.06 [ -0.04, 0.16 ]
Wauben 1998 12 1 (0.1) 13 0.9 (0.2) 10.1 % 0.10 [ -0.02, 0.22 ]
Mukhopadhyay 2007 82 0.83 (0.2) 75 0.75 (0.2) 38.6 % 0.08 [ 0.02, 0.14 ]
Subtotal (95% CI) 283 272 100.0 % 0.08 [ 0.04, 0.12 ]
Heterogeneity: Chi2 = 8.96, df = 7 (P = 0.26); I2 =22%
Test for overall effect: Z = 4.21 (P = 0.000026)
2 Trials recruiting only very preterm or VLBW infants
Modanlou 1986 8 1.09 (0.07) 10 0.82 (0.24) 12.8 % 0.27 [ 0.11, 0.43 ]
Polberger 1989 7 1.11 (0.13) 7 0.94 (0.25) 7.2 % 0.17 [ -0.04, 0.38 ]
Mukhopadhyay 2007 82 0.83 (0.2) 75 0.75 (0.2) 80.0 % 0.08 [ 0.02, 0.14 ]
Subtotal (95% CI) 97 92 100.0 % 0.11 [ 0.05, 0.17 ]
Heterogeneity: Chi2 = 5.22, df = 2 (P = 0.07); I2 =62%
Test for overall effect: Z = 3.88 (P = 0.00011)
3 Trials conducted in low- or middle-income countries
Mukhopadhyay 2007 82 0.83 (0.2) 75 0.75 (0.2) 100.0 % 0.08 [ 0.02, 0.14 ]
Subtotal (95% CI) 82 75 100.0 % 0.08 [ 0.02, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.50 (P = 0.012)
Test for subgroup differences: Chi2 = 0.74, df = 2 (P = 0.69), I2 =0.0%
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Analysis 1.4. Comparison 1 Fortified breast milk versus unfortified breast milk, Outcome 4 Weight at 12 to
18 months (kg).
Review: Multi-nutrient fortiﬁcation of human milk for preterm infants
Comparison: 1 Fortiﬁed breast milk versus unfortiﬁed breast milk
Outcome: 4 Weight at 12 to 18 months (kg)
Study or subgroup Fortiﬁed Unfortiﬁed
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lucas 1996 125 10.05 (1.34) 120 10.09 (1.1) 84.2 % -0.04 [ -0.35, 0.27 ]
Wauben 1998 12 9 (0.9) 13 9 (0.9) 15.8 % 0.0 [ -0.71, 0.71 ]
Total (95% CI) 137 133 100.0 % -0.03 [ -0.31, 0.25 ]
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.81)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Fortified breast milk versus unfortified breast milk, Outcome 5 Length at 12 to
18 months (cm).
Review: Multi-nutrient fortiﬁcation of human milk for preterm infants
Comparison: 1 Fortiﬁed breast milk versus unfortiﬁed breast milk
Outcome: 5 Length at 12 to 18 months (cm)
Study or subgroup Fortiﬁed Unfortiﬁed
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lucas 1996 125 80 (3.35) 120 80.1 (3.29) 90.0 % -0.10 [ -0.93, 0.73 ]
Wauben 1998 12 74.9 (3.7) 13 75.9 (2.5) 10.0 % -1.00 [ -3.50, 1.50 ]
Total (95% CI) 137 133 100.0 % -0.19 [ -0.98, 0.60 ]
Heterogeneity: Chi2 = 0.45, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Fortified breast milk versus unfortified breast milk, Outcome 6 Head
circumference at 12 to 18 months (cm).
Review: Multi-nutrient fortiﬁcation of human milk for preterm infants
Comparison: 1 Fortiﬁed breast milk versus unfortiﬁed breast milk
Outcome: 6 Head circumference at 12 to 18 months (cm)
Study or subgroup Fortiﬁed Unfortiﬁed
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lucas 1996 125 48 (1.12) 120 48.1 (1.1) 98.6 % -0.10 [ -0.38, 0.18 ]
Wauben 1998 12 46.9 (3.9) 13 46.8 (1.3) 1.4 % 0.10 [ -2.22, 2.42 ]
Total (95% CI) 137 133 100.0 % -0.10 [ -0.37, 0.18 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Fortified breast milk versus unfortified breast milk, Outcome 7 Mental
development index at 18 months.
Review: Multi-nutrient fortiﬁcation of human milk for preterm infants
Comparison: 1 Fortiﬁed breast milk versus unfortiﬁed breast milk
Outcome: 7 Mental development index at 18 months
Study or subgroup Fortiﬁed Unfortiﬁed
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lucas 1996 125 106 (22.4) 120 103.8 (21.9) 100.0 % 2.20 [ -3.35, 7.75 ]
Total (95% CI) 125 120 100.0 % 2.20 [ -3.35, 7.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Fortified breast milk versus unfortified breast milk, Outcome 8 Psychomotor
development index at 18 months.
Review: Multi-nutrient fortiﬁcation of human milk for preterm infants
Comparison: 1 Fortiﬁed breast milk versus unfortiﬁed breast milk
Outcome: 8 Psychomotor development index at 18 months
Study or subgroup Fortiﬁed Unfortiﬁed
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lucas 1996 125 92.3 (17.9) 120 89.9 (16.4) 100.0 % 2.40 [ -1.90, 6.70 ]
Total (95% CI) 125 120 100.0 % 2.40 [ -1.90, 6.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Fortified breast milk versus unfortified breast milk, Outcome 9 Length of
hospital stay (weeks).
Review: Multi-nutrient fortiﬁcation of human milk for preterm infants
Comparison: 1 Fortiﬁed breast milk versus unfortiﬁed breast milk
Outcome: 9 Length of hospital stay (weeks)
Study or subgroup Fortiﬁed Unfortiﬁed
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 All trials
Zuckerman 1994 29 7.86 (2) 24 7.43 (1.57) 31.9 % 0.43 [ -0.53, 1.39 ]
Mukhopadhyay 2007 82 4.56 (2.31) 75 4.2 (1.89) 68.1 % 0.36 [ -0.30, 1.02 ]
Total (95% CI) 111 99 100.0 % 0.38 [ -0.16, 0.93 ]
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.38 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Fortified breast milk versus unfortified breast milk, Outcome 10 Feed
intolerance.
Review: Multi-nutrient fortiﬁcation of human milk for preterm infants
Comparison: 1 Fortiﬁed breast milk versus unfortiﬁed breast milk
Outcome: 10 Feed intolerance
Study or subgroup Fortiﬁed Unfortiﬁed Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 All trials
Gross 1987 (1) 0/10 0/10 Not estimable
Gross 1987 (2) 4/21 0/9 2.7 % 4.09 [ 0.24, 68.94 ]
Polberger 1989 1/9 1/8 4.2 % 0.89 [ 0.07, 12.00 ]
Wauben 1998 2/15 0/16 1.9 % 5.31 [ 0.28, 102.38 ]
Mukhopadhyay 2007 17/82 22/75 91.2 % 0.71 [ 0.41, 1.23 ]
Subtotal (95% CI) 137 118 100.0 % 0.90 [ 0.54, 1.49 ]
Total events: 24 (Fortiﬁed), 23 (Unfortiﬁed)
Heterogeneity: Chi2 = 3.21, df = 3 (P = 0.36); I2 =7%
Test for overall effect: Z = 0.43 (P = 0.67)
2 Trials recruiting only very preterm or VLBW infants
Polberger 1989 1/9 1/8 4.4 % 0.89 [ 0.07, 12.00 ]
Mukhopadhyay 2007 17/82 22/75 95.6 % 0.71 [ 0.41, 1.23 ]
Subtotal (95% CI) 91 83 100.0 % 0.71 [ 0.42, 1.22 ]
Total events: 18 (Fortiﬁed), 23 (Unfortiﬁed)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
3 Trials conducted in low- or middle-income countries
Mukhopadhyay 2007 17/82 22/75 100.0 % 0.71 [ 0.41, 1.23 ]
Subtotal (95% CI) 82 75 100.0 % 0.71 [ 0.41, 1.23 ]
Total events: 17 (Fortiﬁed), 22 (Unfortiﬁed)
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
Test for subgroup differences: Chi2 = 0.51, df = 2 (P = 0.78), I2 =0.0%
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Analysis 1.11. Comparison 1 Fortified breast milk versus unfortified breast milk, Outcome 11 Necrotising
enterocolitis.
Review: Multi-nutrient fortiﬁcation of human milk for preterm infants
Comparison: 1 Fortiﬁed breast milk versus unfortiﬁed breast milk
Outcome: 11 Necrotising enterocolitis
Study or subgroup Fortiﬁed Unfortiﬁed Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 All trials
Faerk 2000 1/36 1/40 8.2 % 1.11 [ 0.07, 17.12 ]
Modanlou 1986 2/20 0/19 4.4 % 4.76 [ 0.24, 93.19 ]
Polberger 1989 0/7 0/7 Not estimable
Pettifor 1989 3/53 1/47 9.1 % 2.66 [ 0.29, 24.71 ]
Porcelli 1992 0/7 0/7 Not estimable
Zuckerman 1994 1/29 1/24 9.4 % 0.83 [ 0.05, 12.54 ]
Lucas 1996 8/137 3/138 25.8 % 2.69 [ 0.73, 9.91 ]
Wauben 1998 0/15 0/16 Not estimable
Nicholl 1999 0/13 0/10 Not estimable
Bhat 2003 3/50 5/50 43.1 % 0.60 [ 0.15, 2.38 ]
Mukhopadhyay 2007 0/82 0/75 Not estimable
Subtotal (95% CI) 449 433 100.0 % 1.57 [ 0.76, 3.23 ]
Total events: 18 (Fortiﬁed), 11 (Unfortiﬁed)
Heterogeneity: Chi2 = 3.55, df = 5 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
2 Trials recruiting only very preterm or VLBW infants
Faerk 2000 1/36 1/40 11.0 % 1.11 [ 0.07, 17.12 ]
Modanlou 1986 2/20 0/19 5.9 % 4.76 [ 0.24, 93.19 ]
Polberger 1989 0/7 0/7 Not estimable
Pettifor 1989 3/53 1/47 12.3 % 2.66 [ 0.29, 24.71 ]
Zuckerman 1994 1/29 1/24 12.7 % 0.83 [ 0.05, 12.54 ]
Bhat 2003 3/50 5/50 58.0 % 0.60 [ 0.15, 2.38 ]
Mukhopadhyay 2007 0/82 0/75 Not estimable
Subtotal (95% CI) 277 262 100.0 % 1.19 [ 0.49, 2.88 ]
Total events: 10 (Fortiﬁed), 8 (Unfortiﬁed)
Heterogeneity: Chi2 = 2.35, df = 4 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.71)
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(. . . Continued)
Study or subgroup Fortiﬁed Unfortiﬁed Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
3 Trials conducted in low- or middle-income countries
Pettifor 1989 3/53 1/47 49.2 % 2.66 [ 0.29, 24.71 ]
Zuckerman 1994 1/29 1/24 50.8 % 0.83 [ 0.05, 12.54 ]
Mukhopadhyay 2007 0/82 0/75 Not estimable
Subtotal (95% CI) 164 146 100.0 % 1.73 [ 0.33, 9.11 ]
Total events: 4 (Fortiﬁed), 2 (Unfortiﬁed)
Heterogeneity: Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Chi2 = 0.29, df = 2 (P = 0.87), I2 =0.0%
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Analysis 1.12. Comparison 1 Fortified breast milk versus unfortified breast milk, Outcome 12 Serum ALP
(IU/L): restricted to trials without mineral supplementation of the control group.
Review: Multi-nutrient fortiﬁcation of human milk for preterm infants
Comparison: 1 Fortiﬁed breast milk versus unfortiﬁed breast milk
Outcome: 12 Serum ALP (IU/L): restricted to trials without mineral supplementation of the control group
Study or subgroup Fortiﬁed Unfortiﬁed
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 All trials
Gathwala 2012 30 711 (646) 30 719 (542) 4.6 % -8.00 [ -309.75, 293.75 ]
Modanlou 1986 7 790 (202) 9 1075 (434) 4.1 % -285.00 [ -605.61, 35.61 ]
Mukhopadhyay 2007 82 556 (231) 75 636 (245) 74.7 % -80.00 [ -154.66, -5.34 ]
Pettifor 1989 29 483 (152) 30 843 (514) 11.3 % -360.00 [ -552.07, -167.93 ]
Zuckerman 1994 18 620 (368) 15 881 (435) 5.4 % -261.00 [ -539.14, 17.14 ]
Subtotal (95% CI) 166 159 100.0 % -126.36 [ -190.89, -61.83 ]
Heterogeneity: Chi2 = 9.60, df = 4 (P = 0.05); I2 =58%
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(. . . Continued)
Study or subgroup Fortiﬁed Unfortiﬁed
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Test for overall effect: Z = 3.84 (P = 0.00012)
2 Trials recruiting only very preterm or VLBW infants
Modanlou 1986 7 790 (202) 9 1075 (434) 4.2 % -285.00 [ -605.61, 35.61 ]
Mukhopadhyay 2007 82 556 (231) 75 636 (245) 78.3 % -80.00 [ -154.66, -5.34 ]
Pettifor 1989 29 483 (152) 30 843 (514) 11.8 % -360.00 [ -552.07, -167.93 ]
Zuckerman 1994 18 620 (368) 15 881 (435) 5.6 % -261.00 [ -539.14, 17.14 ]
Subtotal (95% CI) 136 129 100.0 % -132.03 [ -198.09, -65.98 ]
Heterogeneity: Chi2 = 8.98, df = 3 (P = 0.03); I2 =67%
Test for overall effect: Z = 3.92 (P = 0.000089)
3 Trials conducted in low- or middle-income countries
Gathwala 2012 30 711 (646) 30 719 (542) 4.8 % -8.00 [ -309.75, 293.75 ]
Mukhopadhyay 2007 82 556 (231) 75 636 (245) 77.9 % -80.00 [ -154.66, -5.34 ]
Pettifor 1989 29 483 (152) 30 843 (514) 11.8 % -360.00 [ -552.07, -167.93 ]
Zuckerman 1994 18 620 (368) 15 881 (435) 5.6 % -261.00 [ -539.14, 17.14 ]
Subtotal (95% CI) 159 150 100.0 % -119.66 [ -185.54, -53.78 ]
Heterogeneity: Chi2 = 8.62, df = 3 (P = 0.03); I2 =65%
Test for overall effect: Z = 3.56 (P = 0.00037)
Test for subgroup differences: Chi2 = 0.07, df = 2 (P = 0.97), I2 =0.0%
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Analysis 1.13. Comparison 1 Fortified breast milk versus unfortified breast milk, Outcome 13 Bone mineral
content (mg/cm): restricted to trials without mineral supplementation of the control group.
Review: Multi-nutrient fortiﬁcation of human milk for preterm infants
Comparison: 1 Fortiﬁed breast milk versus unfortiﬁed breast milk
Outcome: 13 Bone mineral content (mg/cm): restricted to trials without mineral supplementation of the control group
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Pettifor 1989 29 59 (13) 30 47 (9) 100.0 % 12.00 [ 6.28, 17.72 ]
Total (95% CI) 29 30 100.0 % 12.00 [ 6.28, 17.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.11 (P = 0.000040)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Search strategy
An updated de-duplicated search of MEDLINE via PubMed, EMBASE, CINAHL and The Cochrane Library (2016, Issue 2)
Searched 29/02/16, using the search terms below, yielded 93 new articles.
MEDLINE and MEDLINE In-Process
Searched 09/12/14 via OVID interface.
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) <1946 to Present>
Search Strategy:
1 exp Infant, Newborn/ (513323)
2 Premature Birth/ (7404)
3 (neonat$ or neo nat$).ti,ab. (205534)
4 (newborn$ or new born$ or newly born$).ti,ab. (136536)
5 (preterm or preterms or pre term or pre terms).ti,ab. (50338)
6 (preemie$ or premie or premies).ti,ab. (118)
7 (prematur$ adj3 (birth$ or born or deliver$)).ti,ab. (12271)
8 (low adj3 (birthweight$ or birth weight$)).ti,ab. (26861)
9 (lbw or vlbw or elbw).ti,ab. (5920)
10 infan$.ti,ab. (348181)
11 (baby or babies).ti,ab. (54731)
12 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 (862662)
13 Milk, Human/ (16063)
14 Food, Fortiﬁed/ (7944)
15 13 and 14 (396)
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16 ((fortif$ or supplemented or supplementation) adj4 ((human or breast or expressed) adj2 milk)).ti,ab. (566)
17 15 or 16 (781)
18 12 and 17 (730)
EMBASE
Searched 09/12/14 via OVID interface.
Database: Embase <1974 to 2014 Week 49>
Search Strategy:
1 exp newborn/ (475396)
2 prematurity/ (74237)
3 (neonat$ or neo nat$).ti,ab. (245289)
4 (newborn$ or new born$ or newly born$).ti,ab. (158274)
5 (preterm or preterms or pre term or pre terms).ti,ab. (62693)
6 (preemie$ or premie or premies).ti,ab. (159)
7 (prematur$ adj3 (birth$ or born or deliver$)).ti,ab. (15319)
8 (low adj3 (birthweight$ or birth weight$)).ti,ab. (30730)
9 (lbw or vlbw or elbw).ti,ab. (7192)
10 infan$.ti,ab. (394252)
11 (baby or babies).ti,ab. (69392)
12 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 (929097)
13 breast milk/ (20455)
14 diet supplementation/ (65275)
15 13 and 14 (863)
16 ((fortif$ or supplemented or supplementation) adj4 ((human or breast or expressed) adj2 milk)).ti,ab. (677)
17 15 or 16 (1404)
18 12 and 17 (1194)
CINAHL Plus
Searched 09/12/14 via EBSCO interface, Search modes - Boolean/Phrase.
Search Strategy:
S17 S11 AND S16 (222)
S16 S14 OR S15 (243)
S15 TI ( ((fortif* or supplemented or supplementation) N4 ((human or breast or expressed) N2 milk)) ) OR AB ( ((fortif* or
supplemented or supplementation) N4 ((human or breast or expressed) N2 milk)) ) (153)
S14 S12 AND S13 (141)
S13 (MH “Food, Fortiﬁed”) (2,431)
S12 (MH “Milk, Human”) (3,457)
S11 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 (139,268)
S10 TI ( (baby or babies) ) OR AB ( (baby or babies) ) (17,329)
S9 TI infan* OR AB infan* (54,724)
S8 TI ( (lbw or vlbw or elbw) ) OR AB ( (lbw or vlbw or elbw) ) (1,486)
S7 TI ( (low N3 (birthweight* or birth weight*)) ) OR AB ( (low N3 (birthweight* or birth weight*)) ) (6,186)
S6 TI ( (prematur* N3 (birth* or born or deliver*)) ) OR AB ( (prematur* N3 (birth* or born or deliver*)) ) (2,040)
S5 TI ( (preemie* or premie or premies) ) OR AB ( (preemie* or premie or premies) ) (194)
S4 TI ( (preterm or preterms or pre term or pre terms) ) OR AB ( (preterm or preterms or pre term or pre terms) ) (14,213)
S3 TI ( (newborn* or new born* or newly born*) ) OR AB ( (newborn* or new born* or newly born*) ) (14,806)
S2 TI ( (neonat* or neo nat*) ) OR AB ( (neonat* or neo nat*) ) (29,882)
S1 (MH “Infant, Newborn+”) OR (MH “Infant, Premature”) (86,648)
Maternity and Infant Care
Searched 09/12/14 via OVID interface.
Database: Maternity and Infant Care <1971 to October 2014>
Search Strategy:
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1 ((fortif$ or supplemented or supplementation) adj4 ((human or breast or expressed) adj2 milk)).ti,ab. (221)
WH A T ’ S N E W
Last assessed as up-to-date: 29 February 2016.
Date Event Description
21 March 2016 New citation required and conclusions have changed This review updates the review titled “Multicomponent
fortiﬁed human milk for promoting growth in preterm
infants” (Kuschel 2009)
H I S T O R Y
Protocol ﬁrst published: Issue 4, 1998
Review ﬁrst published: Issue 4, 1998
Date Event Description
29 August 2003 New search has been performed This review updates the existing review titled “Multicomponent fortiﬁed hu-
manmilk for promoting growth in preterm infants”, published inThe Cochrane
Library, Issue 4, 1998
This review presents 6 new studies (included - Zuckerman, Nicholl, Faerk;
excluded - Gupta, Porcelli, Reiss) and 1 follow-up report (Wauben)
C O N T R I B U T I O N S O F A U T H O R S
Jennifer Brown and William McGuire screened and appraised reports identiﬁed in the updated search, extracted and analysed data
from included studies and drafted the review. Nick Embleton and Jane Harding arbitrated inclusion and data extraction disagreements
and drafted the review.
D E C L A R A T I O N S O F I N T E R E S T
None.
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S O U R C E S O F S U P P O R T
Internal sources
• University of York, UK.
• University of Auckland, New Zealand.
• Newcastle Hospitals NHS Foundation Trust and University of Newcastle, UK.
External sources
• National Institute of Health Research (NIHR), UK.
This report describes independent research funded by a UK NIHR Cochrane Programme Grant (13/89/12). The views expressed in
this publication are those of the review authors and are not necessarily those of the NHS, the NIHR or the UK Department of Health
• Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health,
Department of Health and Human Services, USA.
Editorial support of the Cochrane Neonatal Review Group has been funded with Federal funds from the Eunice Kennedy Shriver
National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human
Services, USA, under Contract No. HHSN275201100016C
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We deﬁned “multi-nutrient” fortiﬁer as one that contains both protein and carbohydrate or fat (non-protein energy) with the option
of including other nutrients, such as minerals, vitamins or electrolytes.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Food, Fortiﬁed; ∗Infant Nutritional Physiological Phenomena; ∗Milk, Human [chemistry]; Infant, Premature [∗growth & develop-
ment]; Randomized Controlled Trials as Topic
MeSH check words
Humans; Infant, Newborn
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